Molecular Diagnostics News and Research

RSS

Rice scientists develop new tool to analyze thermal behaviors of DNA and RNA strands

Rice University scientists have developed a tool to speed the design of molecular diagnostics that depend on the specific recognition of pathogen DNA and RNA.

20 Jan 2016

Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept, Inc., a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

7 Jan 2016

Biocept agrees $15 million common stock purchase deal with Aspire

Biocept, Inc., a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, announces a $15 million common stock purchase agreement with Aspire Capital Fund, LLC, a Chicago-based institutional investor.

22 Dec 2015

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy.

22 Dec 2015

Roche's cobas HIV-1 viral load test approved by FDA for use on cobas 6800 and cobas 8800 Systems

Roche announced today that it has received FDA approval for the cobas HIV-1 viral load test by the United States Food and Drug Administration for use on the cobas 6800 and cobas 8800 Systems. This HIV-1 viral load test is part of the next generation of Roche viral load tests, which clinicians use to manage the disease and treatment of patients infected with HIV-1.

21 Dec 2015

New study finds a reason for ethnic disparity in CF diagnoses

Cystic fibrosis (CF) occurs less frequently in nonwhites than in whites, and nonwhites tend to be diagnosed at a later age. This late diagnosis often comes only once they have become symptomatic, rather than through newborn screening programs or molecular diagnostic testing.

16 Dec 2015

Can Nanostructured Microelectrodes be Used to Analyze Biomarkers? An Interview with Dr Shana Kelley

Electrochemical methods are appealing because simple and inexpensive instrumentation can be used to make highly sensitive measurements. However, it has been quite difficult to realize clinically-relevant levels of sensitivity using electrochemistry in highly complex, real-world samples.

From Pittcon 15 Dec 2015

Roka Bioscience reports revenue of $1.5 million for third quarter 2015

Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today reported its financial results for the quarter and nine months ended September 30, 2015.

12 Nov 2015

Biocept receives European patent covering antibody usage in capture of rare cells

Biocept, Inc., a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that the European Patent Office has awarded the patent, "DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS," as announced in the European Bulletin dated November 11, 2015.

11 Nov 2015

Pittcon will exhibit at the Bioconference clinical diagnostics and research virtual conference

Pittcon is pleased to announce its participation in the “Clinical Diagnostics & Research” virtual conference from November 11 to 12, 2015. Clinicians, researchers, medical experts, and professionals from around the world convene for this free web-conference to learn and interact with a community of like-minded colleagues.

From Pittcon 27 Oct 2015

UNITAID report examines new technologies, key market challenges to improved access to better TB diagnostics

More than 50 companies are actively developing new products to diagnose tuberculosis (TB), a disease that killed 1.5 million people in 2013, but many countries still rely on older sputum-based methods, according to a report published by UNITAID.

20 Oct 2015

Brown University researchers describe new method to test HIV mutations

Tests that can distinguish whether HIV-positive people are infected with a drug-resistant strain or a non-resistant strain allow patients to get the most effective treatment as quickly as possible. In the November edition of the Journal of Molecular Diagnostics, a team of Brown University researchers describes a new method that works faster and more sensitively in lab testing than the current standard technologies.

16 Oct 2015

EKF’s PointMan™ used in cancer biopsy research

EKF, announces results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research.

From EKF Diagnostics 15 Oct 2015

RE.WORK showcases future technology and innovations in deep learning software

The future of technological innovation is a broad topic with endless opportunities in every scientific field. RE.WORK’s two most recent concurrent conferences ‘RE.WORK: Future Technology’ and ‘RE.WORK: Deep Learning’, in part focussed on putting healthcare in the context of the wider technological revolution.

13 Oct 2015

MiNDERA closes $1 million Seed financing round

MiNDERA Corp., a leader in non-invasive molecular diagnostics for dermatology and skin-related cancers, announced today the close of its $1 million Seed financing round. Scientific Health Development and other individual investors are among MiNDERA's new investors. This financing round will enable MINDERA to further validate its proprietary micro-needle technology and prepare for the launch of its first research products.

12 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

Ambry Genetics presents groundbreaking TP53 gene data at ASHG; TP53 linked to breast cancer

Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, has announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.

9 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

New smartphone-based device can reliably perform molecular diagnoses at low cost

NIBIB-funded researchers at the Massachusetts General Hospital have developed a smartphone-based device that can reliably carry out molecular diagnoses in under an hour for approximately two dollars per patient. The device could enable point-of-care cancer diagnostics in low- to middle-income or remote areas, which often have high rates of mortality from cancer due to missed opportunities for treatment.

6 Oct 2015

New study finds that serum miRNA profiles change as myeloma progresses

Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.

30 Sep 2015